Media
-
In Stockhead: Race Oncology races ahead in FY24 with key milestones
Race Oncology is pleased to release the FY24 annual report. Key highlights include: Read the full report via this link.
-
Race featured in Stockhead’s Investor Guide: Health & Biotech FY25
Race is pleased to be featured in Stockhead’s Investor Guide this year. The Investor Guide showcases strong forces from the Australian health and biotech sector, offering deep insights to ASX investors. In this feature, Race CEO Dr Daniel Tillett shares the company’s journey of discovering and developing lead asset bisantrene, a unique drug for its…
-
Proactive: Race Oncology receives positive results from AML trial of Bisantrene
Race CEO Dr Daniel Tillett speaks with Jonathan Jackson in the Proactive studio to discuss positive results from an investigator-sponsored Phase 1b/2 trial of RC110 bisantrene for acute myeloid leukaemia (AML). Read the article here, and watch the full interview below.
-
The Australian reports the successful conclusion of Race’s lead drug AML study
The Australian reports the conclusion of Race’s Phase 1b/2 investigator-sponsored trial of RC110 bisantrene in relapsed or refractory acute myeloid leukaemia patients, conducted at the Chaim Sheba Medical Centre in Israel and led by Professor Arnon Nagler. The results show that 40% of patients with highly advanced disease showing a response to bisantrene. Read the…
-
Race Executive Director on Disrupt Radio
Race Oncology Executive Director Dr Peter Smith joined Disrupt Radio to discuss building biotech businesses in Australia, what to look out for when investing in biotech businesses, and why Race’s lead drug bisantrene is a unique asset carrying great clinical and commercial potential. You can listen to Dr Smith’s full interview via this link.
-
Proactive: Race Oncology On Track For Clinical Trials Following ‘Excellent’ RC220 Bisantrene Safety And Toxicology Results
Race CEO Dr Daniel Tillett spoke with Johnathan Jackson at Proactive about the completion of GLP studies for RC220 bisantrene. Dr Tillett noted that the studies demonstrated excellent safety profile for RC220 bisantrene. It gives the new formulation of bisantrene IP and protection, moves the drug closer to human clinical trial, and marks a starting…
-
The Australian: Race Moves Closer To Phase 1 Trial With Key CRO Appointment
The Australian reports that Race Oncology has appointed George Clinical as the Contract Research Organisation to support the Phase 1a/1b trial for RC220 bisantrene in solid tumour patients. Read the full article here.
-
Motley Fool: ASX Healthcare Stock Surges 11% On ‘Incredibly Valuable’ FDA News
The Motley Fool reports on the exciting news that Race has received today. The US Food and Drug Administration (FDA) has extended Rare Paediatric Disease Designation to RC220 bisantrene for the treatment of paediatric acute myeloid leukemia. Read the full analysis here.
-
The Australian: Race Oncology Stock Gains On US FDA Milestone
The Australian reports that The US Food and Drug Authority (FDA) has extended Rare Paediatric Disease Designation (RPDD) to Race’s oncology drug RC220 bisantrene for paediatric acute myeloid leukemia (AML). The RPDD in paediatric AML may qualify Race to be eligible for a Priority Review Voucher (PRV). Race’s Executive Director, Dr Peter Smith, explains in…
